Array Biopharma
ARRY
ARRY was delisted on the 29th of July, 2019.
187 hedge funds and large institutions have $1.49B invested in Array Biopharma in 2017 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 61 increasing their positions, 61 reducing their positions, and 21 closing their positions.
119% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 21
34% more capital inflows, than outflows
Capital inflows: $353M | Capital outflows: $263M
12% more funds holding
Funds holding: 167 → 187 (+20)
3.6% more ownership
Funds ownership: 95.04% → 98.64% (+3.6%)
10% more call options, than puts
Call options by funds: $30.6M | Put options by funds: $27.9M
0% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 61
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$65.5M |
| 2 |
Millennium Management
New York
|
+$49.4M |
| 3 |
Avoro Capital Advisors
New York
|
+$38.5M |
| 4 |
Two Sigma Investments
New York
|
+$24.3M |
| 5 |
PointState Capital
New York
|
+$21.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Redmile Group
San Francisco,
California
|
-$41M |
| 2 |
Morgan Stanley
New York
|
-$28.9M |
| 3 |
BVF Inc
San Francisco,
California
|
-$23.7M |
| 4 |
OrbiMed
New York
|
-$20.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.2M |
ARRY Hedge Fund Activity: Q1 2017 in Review
187 of the 4,036 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma (ARRY) for Q1 2017, worth a combined $1.49B — up 5.9% from $1.41B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new ARRY positions and 21 closed out — a net gain of 25 holders — while 61 added to existing stakes and 61 trimmed.
The largest buyer was Vanguard Group, adding an estimated $65.5M. The largest seller was Redmile Group, cutting an estimated $41M.
- 187 institutional investors held Array Biopharma (ARRY) as of Q1 2017, up from 167 in Q4 2016.
- Funds reported $1.49B of Array Biopharma stock for Q1 2017, up 5.9% quarter-over-quarter.
- 46 funds opened new Array Biopharma positions in Q1 2017 and 21 closed out, a net change of +25 holders.
- The largest Array Biopharma buyer in Q1 2017 was Vanguard Group, an estimated $65.5M added.
- The largest Array Biopharma seller in Q1 2017 was Redmile Group, an estimated $41M sold.
Based on aggregated 13F filings for Q1 2017.